Elizabeth H. Weatherman, who serves as a director at Insulet Corp (NASDAQ:PODD), recently executed a notable acquisition of the company's common stock. On June 3, 2026, Ms. Weatherman purchased 3,450 shares of the common stock for a total consideration valued at $497,489.
The transaction details reveal that the acquired shares were bought across a price range spanning from $143.21 to $145 per share. The purchase was structured in two distinct parts. First, 1,607 shares were acquired at a weighted average price of $143.65, with individual transaction prices recorded between $143.21 and $144.13. Separately, an additional 1,843 shares were purchased at a weighted average price of $144.69, reflecting transactions with unit prices ranging from $144.22 to $145.
Following these recent acquisitions, Ms. Weatherman's direct holdings in Insulet common stock have increased to 10,352 shares.
The timing of this director-level purchase comes against a backdrop of market volatility for Insulet. Currently, the company's stock trades at levels just 2% above its 52-week low of $140.63, having declined by 54% over the preceding six months.
From an analytical perspective, some sources suggest that current valuations indicate the stock may be undervalued. Furthermore, recent operational and product developments provide context to Insulet’s market position. The company announced enhancements to its Omnipod 5 Automated Insulin Delivery System, a system that received FDA clearance in December 2025.
These updates include expanding the target glucose setting options to six distinct levels between 100-150 mg/dL, alongside introducing a new 100 mg/dL target glucose option. Data derived from studies involving individuals with both type 1 and type 2 diabetes indicated that these updated settings resulted in an improved median time in range.
The company has also faced certain operational setbacks. A voluntary recall was issued affecting approximately 7 million Omnipod insulin pods due to a reported manufacturing defect. This recall impacts specific lots of three product lines: Omnipod 5, Omnipod DASH, and Omnipod Eros pods. However, the extent of the impact appears limited, as roughly 60% of the affected pods were already consumed or had expired.
Despite these challenges, external financial assessments have maintained a degree of confidence. Benchmark recently upheld a Buy rating on Insulet, setting a price target of $250. Meanwhile, William Blair initiated coverage of Insulet with an Outperform rating. The firm's report specifically noted that the stock is trading lower relative to its peers, even while exhibiting faster sales growth.
William Blair also provided valuation context, pointing out that the company’s shares are trading at 24 times its projected 2026 earnings per share estimate. These multifaceted developments offer investors several areas of focus when assessing Insulet's current market standing and product performance trajectory.